An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus

Trial Profile

An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Darapladib (Primary)
  • Indications Atherosclerosis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top